Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. The company operates in a single segment: human therapeutics. Principal products include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL (co-promoted with Wyeth).
Key Financial Metrics
| Metric (in millions) | Q1 2005 | Q1 2004 |
|---|---|---|
| Total Revenues | $2,833 | $2,343 |
| Product Sales | $2,735 | $2,208 |
| Operating Income | $1,156 | $928 |
| Net Income | $854 | $690 |
| Diluted EPS | $0.67 | $0.52 |
| Operating Cash Flow | $1,123 | $399 |
| Cash & Marketable Securities | $4,035 | $5,808 (Dec 31, 2004) |
| Total Debt (Current + Long-term) | $3,942 | $5,110 (Dec 31, 2004) |
Margins: Operating income as a percentage of product sales was 42% for Q1 2005, consistent with Q1 2004. The effective tax rate was 25.5% in Q1 2005, down from 27.3% in Q1 2004.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 21% year-over-year, driven primarily by a 24% increase in product sales. International sales grew 29%, benefiting from a $28 million favorable foreign currency impact.
- Product Performance:
- Aranesp: Sales increased 33% to $723 million, driven by market share gains in oncology and nephrology.
- ENBREL: Sales surged 49% to $592 million, fueled by growth in rheumatology and dermatology markets.
- Neulasta: Sales rose 27% to $501 million.
- EPOGEN: U.S. sales declined 1% to $583 million due to revised estimates of dialysis demand and wholesaler inventory adjustments.
- Expenses: Operating expenses increased 19% to $1,677 million. R&D expenses rose 19% (to $524 million) due to staff additions from the Tularik merger and clinical trial ramp-ups. SG&A increased 12% (to $577 million) primarily due to higher marketing expenses and Wyeth profit share related to ENBREL growth.
- Debt Reduction: On March 2, 2005, Amgen repurchased $1.59 billion aggregate principal amount of Convertible Notes for $1.175 billion in cash, reducing outstanding debt.
- Stock Repurchases: The company repurchased 27 million shares for $1.675 billion in Q1 2005, compared to 10 million shares for $650 million in Q1 2004.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management expects sales growth to continue to be driven by Aranesp, ENBREL, and Neulasta. However, they anticipate that reimbursement changes resulting from the Medicare Modernization Act (MMA) could negatively affect product sales for the remainder of 2005. Specifically, Average Sales Price (ASP) reimbursement rates for Aranesp, Neulasta, and NEUPOGEN are expected to trend downward throughout 2005 before stabilizing late in the year.
Risks and Contingencies
- Reimbursement Policy Changes: The MMA and potential changes to the Hematocrit Measurement Audit Program (HMA-PM) pose risks to EPOGEN and other product utilization. The company cannot predict the full impact of these changes.
- Supply Constraints: ENBREL supply is dependent on third-party manufacturers (Boehringer Ingelheim) and the company's Rhode Island facility. Supply interruptions could materially affect sales.
- Patent Expirations: European patents for erythropoietin expired in December 2004, and G-CSF patents expire in August 2006, potentially exposing the company to biosimilar competition in Europe.
- Legal Proceedings: The company faces litigation regarding Average Wholesale Price (AWP) reporting and patent disputes (e.g., Israel Bio-Engineering Project). While no material adverse effect on annual statements is expected, quarterly impacts are possible.
- Accounting Changes: The company is evaluating the adoption of SFAS No. 123R (Share-Based Payment), which will require fair-value accounting for stock options and is expected to have a material impact on results of operations upon adoption (required by Jan 1, 2006).
Unusual Items
In April 2005 (subsequent to the period end), Amgen made an offer to exchange existing Convertible Notes for new zero-coupon senior convertible notes with different convertibility terms and cash settlement requirements.
Investor Verification Checklist
- Reimbursement Impact: Verify the actual impact of the MMA ASP changes on Q2 and Q3 2005 sales for Aranesp, Neulasta, and NEUPOGEN.
- ENBREL Supply Chain: Monitor updates on the regulatory approval status of the new Rhode Island manufacturing facility and the Wyeth facility in Ireland to ensure supply continuity.
- Convertible Note Exchange: Track the acceptance rate of the April 2005 exchange offer for Convertible Notes and the resulting capital structure changes.
- Patent Litigation: Review developments in the Israel Bio-Engineering Project appeal and AWP litigation for potential financial liabilities.
- Stock-Based Compensation: Assess the timeline and financial impact of the eventual adoption of SFAS 123R on reported net income.